Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 538-543

  Farzaneh Far, Ramin ^a   Harris, William S ^b   Garg, Sachin ^a   Na, Beeya ^c   Whooley, Mary A ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

C reactive protein; Fish oil; Inflammation; Interleukin 6; Omega 3

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ERYTHROCYTE MEMBRANE; FEMALE; HEART PROTECTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 67650876215     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.013     Document Type: Article

References (39)

1. Breslow J.L. N-3 fatty acids and cardiovascular disease. Am J Clin Nutr 83(S) (2006) 1477S-1482S
2. Lee J.H., O'Keefe J.H., Lavie C.J., Marchioli R., and Harris W.S. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 83 3 (2008) 324-332
3. Harris W.S., Poston W.C., and Haddock C.K. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193 1 (2007) 1-10
4. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346 (2002) 1113-1118
5. Harris W.S., Miller M., Tighe A.P., Davidson M.H., and Schaefer E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197 1 (2008) 12-24
6. Tsimikas S., Willerson J.T., and Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47 8S (2006) C19-C31
7. Blake G.J., and Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41 4S (2003) 37S-42S
8. Calder P.C. N-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83 S (2006) 1505S-1519S
9. Ruo B., Rumsfeld J.S., Hlatky M.A., Liu H., Browner W.S., and Whooley M.A. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 290 (2003) 215-221
10. Dagenais G.R., Yi Q., Mann J.F., Bosch J., Pogue J., and Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 149 1 (2005) 54-60
11. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 2 (2000) 209-214
12. Zuliani G., Volpato S., Galvani M., et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity: data from the Inchianti study. Atherosclerosis 203 2 (2009) 626-632
13. Casas J.P., Shah T., Hingorani A.D., Danesh J., and Pepys M.B. C-reactive protein and coronary heart disease: a critical review. J Intern Med 264 4 (2008) 295-314
14. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5 4 (2008) e78
15. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2 8666 (1989) 757-761
16. Marchioli R., Barzi F., Bomba E., et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarcto Miocardico (GISSI)-Prevenzione. Circulation 105 16 (2002) 1897-1903
17. Yokoyama M., Origasa H., Matsuzaki M., et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369 9567 (2007) 1090-1098
18. Kris-Etherton P.M., Harris W.S., and Appel L.J. American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 21 (2002) 2747-2757
19. Pischon T., Hankinson S.E., Hotamisligil G.S., Rifai N., Willett W.C., and Timm E.B. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 108 (2003) 155-160
20. Lopez-Garcia E., Schulze M.B., Manson J.E., et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr (2004) 1341806-1341811
21. Ohsawa M., Itai K., Onoda T., et al. Dietary intake of n-3 polyunsaturated fatty acids is inversely associated with CRP levels, especially among male smokers. Atherosclerosis 201 1 (2008) 184-191
22. Niu K., Hozawa A., Kuriyama S., et al. Dietary long-chain n-3 fatty acids of marine origin and serum C-reactive protein concentrations are associated in a population with a rich diet in marine products. Am J Clin Nutr 84 1 (2006) 223-229
23. Mori T.A., Woodman R.J., Burke V., Puddey I.B., Croft K.D., and Beilin L.J. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35 7 (2003) 772-781
24. Madsen T., Christensen J.H., and Schmidt E.B. C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: a placebo-controlled randomized study. Eur J Nutr 46 7 (2007) 428-430
25. Yusof H.M., Miles E.A., and Calder P. Influence of very long chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78 3 (2008) 219-228
26. Satoh N., Shimatsu A., Kotani K., et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 30 1 (2007) 144-146
27. Browning L.M., Krebs J.D., Moore C.S., Mishra G.D., O'Connell M.A., and Jebb S.A. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 9 1 (2007) 70-80
28. Ciubotaru I., Lee Y.S., and Wander R.C. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 14 9 (2003) 513-521
29. Ferrucci L., Cherubini A., Bandinelli S., et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91 (2006) 439-446
30. Madsen T., Skou H.A., Hansen V.E., et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 88 (2001) 1139-1142
31. Block R.C., Harris W.S., and Pottala J.V. Determinants of blood cell omega-3 fatty acid content. Open Biomarkers J 1 (2008) 1-6
32. Endres S., Ghorbani R., Kelley V.E., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320 (1989) 265-271
33. Goldman D.W., Pickett W.C., and Goetzl E.J. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 117 (1983) 282-288
34. Serhan C.N., Hong S., Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196 (2002) 1025-1037
35. Sperling R.I., Benincaso A.I., Knoell C.T., Larkin J.K., Austen K.F., and Robinson D.R. Dietary n-3 polyunsaturated fatty acids inhibit phosphoinositide formation and chemotaxis in neutrophils. J Clin Invest 91 (1993) 651-660
36. Caughey G.E., Mantzioris E., Gibson R.A., Cleland L.G., and James M.J. The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63 (1996) 116-122
37. Massaro M., Habib A., Lubrano L., et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cycloxygenase-2 induction through both NADP(H) oxidase and PKC inhibition. PNAS 103 (2006) 15184-15189
38. Ridker P.M., Fonseca F.A., Genest J., et al. JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 100 11 (2007) 1659-1664
39. Sun Q., Ma J., Campos H., et al. Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am J Clin Nutr 88 (2008) 216-223